# A Phase 2 Study of BNC210 for the Acute Treatment of Social Anxiety Disorder

> **NCT05193409** · PHASE2 · COMPLETED · sponsor: **Bionomics Limited** · enrollment: 151 (actual)

## Conditions studied

- Social Anxiety Disorder

## Interventions

- **DRUG:** 225 mg BNC210
- **DRUG:** 675 mg BNC210
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05193409
- **Lead sponsor:** Bionomics Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-02-02
- **Primary completion:** 2022-10-10
- **Final completion:** 2022-10-17
- **Target enrollment:** 151 (ACTUAL)
- **Last updated:** 2025-03-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05193409

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05193409, "A Phase 2 Study of BNC210 for the Acute Treatment of Social Anxiety Disorder". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT05193409. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*